Discussion  by unknown
Conradi et al Acquired Cardiovascular Diseasetailor-made treatment strategy. Decision for one or the other
treatment option should be made within a heart center by an
interdisciplinary dedicated heart valve team including car-
diologists, cardiac surgeons, cardiac anesthetists, and inten-
sive care physicians and should be independent from any
financial or budget-related bias. It seems likely that with
technical refinement of existing devices and mounting clin-
ical experience of implanting physicians, further improve-
ment of clinical outcome after TAVI can be anticipated.
The question whether this development will justify exten-
sion of the technique to patients with a lower risk profile
cannot be answered at present and warrants the conductance
of further randomized trials.A
C
DLimitations
The present study did not randomize patients to receive
either TAVI or AVR. Therefore, unknown and potentially
confounding variables may have had an impact on out-
comes. However, risk adjustment yielded 2 patient cohorts
that were similar regarding many baseline demographics
and risk factors. The retrospective nature and limited patient
number in this study are further potential limitations.References
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Dr Vinod H. Thourani (Atlanta, Ga).My disclosure is I am an
investigator and on the steering committee for the Edwards PART-
NER trial. I appreciate the opportunity to discuss this important
and timely paper by Dr Conradi and his colleagues fromHamburg,
Germany. I also want to thank the authors for providing me a copy
of their manuscript and the slides in advance.
The authors are to be congratulated for excellent outcomes in
a ‘‘real world’’ scenario outside the confines of a research trial
comparing 82 patients undergoing TAVI within the past year
with 82 propensity-matched surgical AVR patients over an 8- to
9-year period. In this group, the authors performed 62 transapical
and 22 transfemoral valve implantations, information that was not
shown in the slides but is in the manuscript that was given to me.
They noted a respectable overall mortality of 7.3% in the trans-
catheter group and 8.6% in the surgical AVR group. The stroke
rate was 2 patients, or 2.4%, in each group, and transfusion of
less than 1 unit of blood in the transcatheter group, which is excel-
lent. Overall, they have concluded similar results in short-term out-
comes of patients undergoing isolated AVR with an average
Society of Thoracic Surgeons predicted risk of mortality of
approximately 9%. So, again, congratulations are due for those
outcomes.
I have a couple of questions for the authors. First, you note the
paravalvular leak rate comparing the transcatheter valve and the
surgical valve group. Was there an associated morbidity and mor-
tality in those patients, especially in those that have a diminished
ejection fraction? Can you comment on the rate of paravalvular
leakage between the 2 groups?
Dr Conradi. Thank you, Dr Thourani, for those questions.
When looking at regurgitation rates, we found that about 50%ardiovascular Surgery c Volume 143, Number 1 69
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gree of paravalvular leakage. However, in the vast majority of
these patients, in 40 of those, this was trivial to mild and did not
have any clinical consequence. In only 1 patient was there a degree
of paravalvular regurgitation that was graded as moderate. In the
surgical group, we did not see any relevant paravalvular leakage.
The regurgitation that we saw here was central, as is known to oc-
cur with pericardial prostheses.
We did not see any influence on the outcome of these 82
patients.
Dr Thourani. We have had problems with patients who have
low ejection fractions, 20% to 25%. Even when we leave them
with mild aortic regurgitation, they continue to be admitted for
heart failure. It does not seem as though you have seen what we
have seen here in the United States at times.
Dr Conradi. In this cohort, we have not, but I can say that in
patients with pronounced cardiomyopathy, we tend to use the Cor-
eValve device (Medtronic, Inc, Minneapolis, Minn) rather than the
Edwards device because it does not need rapid ventricular pacing
for implantation. We believe that may be advantageous for the pa-
tient, to some extent, and maybe this is the bias that we have. As
a consequence, we do not see the effects that you are alluding to
in this particular cohort of patients receiving Edwards Sapien
valves.
Dr Thourani. It sounds like an interesting paper for next year’s
Association meeting.
Can you note the median valve size used in the surgical AVR
patients as compared with the TAVR patients? Have you seen
any outcome differences with patient–prosthesis mismatch, which
we have already heard about in the valve-in-valve from your site?
Dr Conradi. Thank you for the question. The mean size was
24 mm in the TAVI patients and 22 mm in the surgical patients.
There seems to be a difference, and it is indeed statistically sig-
nificant. However, these are 2 different valve types. If you con-
sider the technique of implantation, for example, a 23-mm TAVI
is not a 23-mm surgical valve. Furthermore, because you also
have to consider the extent of calcification present within the na-
tive valve and annulus, extension of the TAVI device may be dif-
ferent from patient to patient. Therefore, it is hard to draw
conclusions just by the manufacturer-given valve sizes that
were implanted.
Dr Thourani. In the manuscript, you report that a lot of your
patients have size 19 valves. Have you seen any major problems
from the surgical patients having only a 19-mm valve inserted?
Comparably, in the transcatheter patients the smallest valve was
23 mm. Is there any outcomes difference between the patients re-
ceiving 19-mm valves surgically versus the larger valve effective
orifice areas for the transcatheter patients?
Dr Conradi. From the 82 patients in the surgical cohort, 7 re-
ceived 19-mm valves. I do know that, maybe not from these partic-
ular 7 patients but in general from our experience, we did see the
same kind of problems that you were alluding to in our experience,
also. Whenever we can, we try to avoid these small prostheses, es-
pecially now with valve-in-valve technology being an option for
the future in these patients.
Dr Thourani.Although not discussed in your presentation, you
have not really broken out transapical or transfemoral techniques,
so you are putting thewhole transcatheter group into one. Are there70 The Journal of Thoracic and Cardiovascular Surgeany major differences between the transapical and transfemoral
approaches in the surgical AVR group?
Dr Conradi. Yes, we looked into that. The relation, as you
pointed out in the beginning, was 60 transapicals versus 22 trans-
femorals.We did not see amajor difference in this particular subset
of patients regarding outcome, even though the baseline character-
istics may have differed between the 2. We were surprised by that
finding at the beginning, but these are the facts and how we see
them.
Dr Thourani. I guess that leads to the question of what should
be chosen then. Somebody asked that earlier in the previous pre-
sentation. When a patient comes in, looking at your data and the
data presented from other people at this meeting, do you use
a transapical or a transfemoral approach or do you do a surgical
AVR, and how do you make that decision? I presume you are still
putting in surgical valves in patients. How do you make that differ-
entiation from Hamburg? What can we learn from you?
Dr Conradi.We have a transfemoral-first policy at our site, and
we have the same contraindications for that kind of approach as
many other investigators have. Severe peripheral artery disease
may preclude transfemoral access, as may small caliber vessels,
even though the XT device has somewhat diminished that hurdle.
Furthermore, we also look very closely at the aorta; tortuosity or
atherosclerosis or even aneurysm formation of the abdominal aorta
may be a problem, as is severe calcification of the aortic arch. All
in all, we have a pretty liberal stance on using transapical access.
DrMarc R. Moon (St Louis, Mo). You said you have a transfe-
moral-first approach. Is age then irrelevant at your institution?
Dr Conradi. Do you mean for the decision?
Dr Moon. If a 40-year-old patient comes in, does he or she get
a transfemoral-first approach?
Dr Conradi.No. I mean transfemoral first within the TAVI can-
didates. After deciding for TAVI, we have a transfemoral-first
policy.
Dr Moon. Since all your patients were at the same institution,
were you able to perform any cost data comparison?
Dr Conradi. We have a special situation in Germany. Reim-
bursement for TAVI is very high. It is possible that in other insti-
tutions this may be a reason for a TAVI or against surgery. I do
not know. With our approach, it certainly is not. We have the heart
team approach, and we look at each and every one of these patients
with our cardiology colleagues. For example, we would never use
age alone as a criterion for a TAVI or against surgery but rather re-
late that to the general status of the patient and comorbidities and
so on.
Dr Lucian Lozonschi (Madison, Wis). First, was this study
done with only the Edwards Sapien valve or were there any Core-
Valves also? It was not clear from your slides. Second, the mortal-
ity in both groups was high and actually higher than that reported
in the PARTNER trial in the surgical group. I have a question also,
regarding the paravalvular leak. You mentioned there was some
aortic regurgitation. We all know that aortic regurgitation is hard
to assess after TAVI, because there are multiple jets; there is a cen-
tral jet as well as paravalvular jets. And the data in the PARTNER
trial were rigorously checked by an independent core laboratory. In
the real-life situation, it is going to be hard to report how pleased
we are with ‘‘some’’ aortic regurgitation, and I think there may be
more patients with more than mild regurgitation than in yourry c January 2012
Conradi et al Acquired Cardiovascular Diseasegroup. I was struck by the low incidence of paravalvular leak, es-
pecially in the TAVI group. Can you comment, please?
Dr Conradi. Thank you for these important questions. The first
question was whether this was an Edwards-only cohort. As stated
on the methods slide, it was. These were 82 consecutive Edwards
patients. Within the same time frame, we did perform CoreValve
implantations, but these were not included in the study.
Regarding your comment about the PARTNER trial, I agree that
results were more favorable here in that trial. However, if you look
at the study design, there were important exclusion criteria forThe Journal of Thoracic and Cpatients in the PARTNER trial, such as severe heart failure or se-
vere renal insufficiency. We did not have any of these exclusion
criteria. This was a real world experience. If you compare our se-
ries to other series, like the Munich experience, other groups get
results similar to ours with this approach.
Regarding paravalvular leakage, you are completely right that
assessment of paravalvular leakage is not that easy, and grading
is not either. All of these patients were followed in our outpatient
clinic by our cardiology colleagues, and we have deep confidence
that they assess paravalvular leakages in a correct manner.ardiovascular Surgery c Volume 143, Number 1 71
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